Although further analyses will be required to deeply investigate the molecular mechanisms by which PON2 could participate in bladder carcinogenesis, our study clearly demonstrates, for the first time, the impact of the enzyme on tumor progression and the susceptibility of tumor cells to chemotherapeutics, thus suggesting a potential use of PON2 as an interesting molecular target for BC therapy. The gene discussed is PON2; the disease is breast cancer.